Advertisement
Canada markets close in 2 hours 5 minutes

  • S&P/TSX

    21,665.69
    -74.51 (-0.34%)
     

  • S&P 500

    5,052.75
    -9.07 (-0.18%)
     

  • DOW

    37,803.33
    +68.22 (+0.18%)
     

  • CAD/USD

    0.7233
    -0.0020 (-0.28%)
     

  • CRUDE OIL

    85.27
    -0.14 (-0.16%)
     

  • Bitcoin CAD

    86,229.42
    -2,050.20 (-2.32%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,404.40
    +21.40 (+0.90%)
     

  • RUSSELL 2000

    1,965.34
    -10.36 (-0.52%)
     

  • 10-Yr Bond

    4.6800
    +0.0520 (+1.12%)
     

  • NASDAQ

    15,870.09
    -14.93 (-0.09%)
     

  • VOLATILITY

    18.35
    -0.88 (-4.55%)
     

  • FTSE

    7,820.36
    -145.17 (-1.82%)
     

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • CAD/EUR

    0.6810
    -0.0014 (-0.21%)
     
MARKETS LIVE BLOG:

STOCKS TRADE MIXED AS COMPANY EARNINGS ROLL IN

Shares of Live Nation, parent company of Ticketmaster, fall on antitrust probe report

Isolating CBD Through Extraction Presents Extreme as Potential US Federal CBD Legalization Nears

Baystreet.ca
Updated

While the lifting of US federal prohibition on cannabis as a recreational or even medicinal drug may seem a long way away, the wider-scale legalization of a cannabis- and hemp-derived extract cannabidiol (CBD) could be around the corner. Back in April, federal advisors voted to recommend approval of the first prescription CBD medicine, known as Epidiolex—developed by GW Pharmaceuticals plc (OTC: GWPRF). The advisory committee to the Food and Drug Administration’s vote unanimously ... Click here to view full article